# Patrick Burgermeister

> Patrick Burgermeister is a seed investor at BioMedPartners backing Biotechnology and Biopharma. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [BioMedPartners](https://shizune.co/investors/profile/biomedpartners)
- Total investments: 7
- Last investment: Jun 2024
- Lead investor: 71%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/patrick-burgermeister-279aaa2

Patrick Burgermeister is a seed investor at BioMedPartners focused on Biotechnology and Biopharma. Before joining BioMedPartners AG, Mr. Burgermeister worked for Novartis Pharma AG where he was Senior Portfolio Manager in project management.He was responsible for the evaluation of development projects in various stages and indications and served as interface to development finance. Prior to Novartis, he was Senior Financial Analystresponsible for the European Biotech and Pharma sector at Zürcher Kantonalbank. In addition, he served as advisor to the fund Pharma Vision of the same institution. Before that, he worked as strategic planning manager at Jomed AG (now Abbott Laboratories). Today, Mr. Burgermeister holds a Master degree in Molecular Biology from the University of Basel (Biozentrum), a master’s degree in Business Administration from the University of St. Gallen (HSG) and a degree as Chartered Financial Analyst (CFA).

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 71% |
| Biopharma | 3 | 43% |
| Therapeutics | 3 | 43% |
| Life Science | 2 | 29% |
| Medical | 1 | 14% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 43% |
| Pre-Seed | 1 | 14% |
| Series D | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 43% |
| Switzerland | 2 | 29% |
| Germany | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NXI Therapeutics | NXI Therapeutics specializes in the development of innovative immunosuppressive drugs aimed at treating autoimmune diseases and facilitating organ transplantation. The company focuses on creating drugs that offer high efficacy in managing these conditions. With a team led by CEO Ruben Herrendorff, who has extensive experience in preclinical andearly clinical drug research and development, particularly in autoimmune and neuromuscular diseases, NXI Therapeutics is at the forefront of addressing complex medical challenges. The company operates within the biotechnology industry and is committed to advancing the field through its research initiatives. | $4M | Pre-Seed | Jun 18, 2024 |  |
| Reservoir Neuroscience | Reservoir Neuroscience is a biopharma company that develops novel therapeutics to repair dysfunctional blood vessels in the brain. Reservoir Neuroscience was founded in 2019 and is based in Emeryville, California. | $4M | Venture - Series Unknown | Jan 18, 2024 |  |
| Invasight | Invasight is a clinical biotech company that focused on revolutionizing cell invasion research. The company was founded in 2019 and is headquartered in Zurich, Switzerland. | $4.6M | Seed | Jun 07, 2022 |  |
| Elastrin Therapeutics | Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work.The company's proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improvesthe efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. | $10M | Seed | Apr 07, 2022 |  |
| Revel Pharmaceuticals | Revel develops therapeutics for multiple diseases of aging including osteoarthritis, kidney disease, cardiovascular disease, skin aging, and complications of diabetes. It is commercializing therapeutic enzymes to degrade age-associated molecule damage. It was founded in 2019 and is based in San Francisco, California. | $8.4M | Seed | Mar 17, 2022 |  |
| Staffbase | Staffbase provides an internal communications platform to help companies and their employees work together toward a common goal. Staffbase supports industry leaders with their own branded app to engage their diverse, disconnected, and distributed workforce. The company was founded in 2014 and is headquartered in Chemnitz with offices in Dresden,Cologne, and New York. | $143.6M | Series D | Mar 29, 2021 |  |
| Elastrin Therapeutics | Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work.The company's proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improvesthe efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. | $2.5M | Seed | Mar 04, 2021 |  |

7 of 7 investments shown.

## Co-investors
- [Capnamic](https://shizune.co/investors/profile/capnamic-ventures) — VC Fund, 2 deals together
- [General Atlantic](https://shizune.co/investors/profile/general-atlantic) — VC Fund, 2 deals together
- [Starbloom Capital](https://shizune.co/investors/profile/starbloom-capital) — VC Fund, 2 deals together
- [Verve Ventures](https://shizune.co/investors/profile/verve-ventures) — VC Fund, 2 deals together
- [AVANTECA Partners](https://shizune.co/investors/profile/avanteca-partners) — VC Fund, 1 deal together
- [BaseLaunch](https://shizune.co/investors/profile/baselaunch) — VC Fund, 1 deal together

## About BioMedPartners

VC Fund · Basel, Switzerland

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

5 contacts available at BioMedPartners.

| Name | Title | Profile |
| --- | --- | --- |
| Fiona Lauscher | Office Manager | https://shizune.co/investors/profile/fiona-lauscher |
| Karl Deres | Venture Partner | https://shizune.co/investors/profile/karl-deres |
| Markus Hosang | General Partner | https://shizune.co/investors/profile/markus-hosang |
| Patrick Burgermeister | Partner | https://shizune.co/investors/profile/patrick-burgermeister |
| Stefan Fäs | Chief Financial Officer & Partner | https://shizune.co/investors/profile/stefan-fs |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Patrick Burgermeister invest in?

Patrick Burgermeister invests primarily in Biotechnology, Biopharma and Therapeutics startups, most often at Seed and Pre-Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Patrick Burgermeister last invest?

The most recent investment recorded for Patrick Burgermeister closed in Jun 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co